Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

Xiao, Zheng; Wang, Cheng-Qiong; Li, Lianhong; Tang, Xuemei; Li, Nana; Li, Jing; Chen, Ling; Gong, Qihai; Tang, Fushan; Feng, Jing; Li, Xiaofei

doi:10.1155/2018/7918258

Cited by 18 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixth, virtual patient blended learning had an overall positive pooled effect when compared to traditional learning on knowledge outcomes; this was also found in a similar meta-analysis [ 93 ]. Our observations also supplement the evidence in previous reviews [ 94 , 95 ] which included studies since 2010. Nevertheless, virtual patient simulations predominantly affect skill rather than knowledge outcomes.…”

Section: Discussionsupporting

confidence: 89%

Blended Learning Compared to Traditional Learning in Medical Education: Systematic Review and Meta-Analysis

Vallée¹,

Blacher²,

Cariou³

et al. 2020

J Med Internet Res

284

230

View full text Add to dashboard Cite

Background Blended learning, which combines face-to-face learning and e-learning, has grown rapidly to be commonly used in education. Nevertheless, the effectiveness of this learning approach has not been completely quantitatively synthesized and evaluated using knowledge outcomes in health education. Objective The aim of this study was to assess the effectiveness of blended learning compared to that of traditional learning in health education. Methods We performed a systematic review of blended learning in health education in MEDLINE from January 1990 to July 2019. We independently selected studies, extracted data, assessed risk of bias, and compared overall blended learning versus traditional learning, offline blended learning versus traditional learning, online blended learning versus traditional learning, digital blended learning versus traditional learning, computer-aided instruction blended learning versus traditional learning, and virtual patient blended learning versus traditional learning. All pooled analyses were based on random-effect models, and the I2 statistic was used to quantify heterogeneity across studies. Results A total of 56 studies (N=9943 participants) assessing several types of learning support in blended learning met our inclusion criteria; 3 studies investigated offline support, 7 studies investigated digital support, 34 studies investigated online support, 8 studies investigated computer-assisted instruction support, and 5 studies used virtual patient support for blended learning. The pooled analysis comparing all blended learning to traditional learning showed significantly better knowledge outcomes for blended learning (standardized mean difference 1.07, 95% CI 0.85 to 1.28, I2=94.3%). Similar results were observed for online (standardized mean difference 0.73, 95% CI 0.60 to 0.86, I2=94.9%), computer-assisted instruction (standardized mean difference 1.13, 95% CI 0.47 to 1.79, I2=78.0%), and virtual patient (standardized mean difference 0.62, 95% CI 0.18 to 1.06, I2=78.4%) learning support, but results for offline learning support (standardized mean difference 0.08, 95% CI –0.63 to 0.79, I2=87.9%) and digital learning support (standardized mean difference 0.04, 95% CI –0.45 to 0.52, I2=93.4%) were not significant. Conclusions From this review, blended learning demonstrated consistently better effects on knowledge outcomes when compared with traditional learning in health education. Further studies are needed to confirm these results and to explore the utility of different design variants of blended learning.

show abstract

Section: Discussionsupporting

confidence: 89%

Blended Learning Compared to Traditional Learning in Medical Education: Systematic Review and Meta-Analysis

Vallée¹,

Blacher²,

Cariou³

et al. 2020

J Med Internet Res

284

230

View full text Add to dashboard Cite

show abstract

“…The results from clinical and basic studies revealed that Aidi has an important antitumor, immunoregulatory, anti-inflammatory and antioxidative stress function (Duan et al, 2018b;Li et al, 2018;Zhou et al, 2018;Xiao et al, 2019a;Chen et al, 2019;Farag et al, 2019;Huang et al, 2019;Li et al, 2019;Qu et al, 2019;Zhang et al, 2019). The results of previous SRs/meta-analyses (Ma et al, 2009;Xiao et al, 2016;Wu et al, 2017a;Xiao et al, 2018a;Xiao et al, 2018b;Wang et al, 2018;Xiao et al, 2019b) demonstrated that Aidi in combination with chemotherapy showed significant improvements in tumor response, QOL, and OS rate, and decreases in ADRs. Recently, we found that Aidi in combination with NP might improve the tumor response and QOL, upregulate antitumor immunity, and reduce the incidence of hematotoxicity and gastrointestinal and liver toxicity in patients with NSCLC (Xiao et al, 2020b).…”

Section: Discussionmentioning

confidence: 99%

The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).Objectives: We performed a new evaluation to demonstrate the clinical efficacy and safety of the Aidi and GP combination and further explored an optimal strategy for achieving an ideal response and safety level in advanced NSCLC.Methodology: We collected all the related trials from Chinese and English-language databases, analyzed their methodological bias risk using the Cochrane evaluation Handbook for Systematic Reviews of Interventions Version 5.1.0, extracted all the data using a predefined data extraction form, pooled the data using a series of meta-analyses, and finally summarized the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.Results: We included 70 trials with 5,509 patients. Compared with GP alone, the Aidi and GP combination showed a significant improvement in the objective response rate (ORR) [1.82 (1.62–2.04)], disease control rate (DCR) [2.29 (1.97–2.67)], and quality of life (QOL) [3.03 (2.55–3.60)] and a low incidence of hematotoxicity and gastrointestinal and hepatorenal toxicity. Aidi might be more suitable for patients who are first-treated, elderly, or patients with a Karnofsky Performance Status (KPS) score ≥ 60 or anticipated survival time (AST) ≥3 months. An Aidi (50 ml/day, 7–14 days/cycle for one to two cycles), gemcitabine (1000 mg/m2), and cisplatin (20–30 mg/m2, 40–50 mg/m2, or 60–80 mg/m2) might be an optimal regimen for realizing an ideal response and safety level. Most results were robust and of moderate quality.Conclusion: Current evidence indicates that Aidi's value in adjuvant chemotherapy may be broad-spectrum, not just for some regimens. The Aidi and GP combination may show a good short-term response, antitumor immunity, and safety level in patients with NSCLC. Aidi (50 ml/day, 7–14 days/cycle for one and two cycles) with GEM (1000 mg/m2) and DDP (20–30 mg/m2 or 40–50 mg/m2) may be an optimal regimen for realizing an ideal goal in patients who are first-treatment, elderly, or have a KPS score ≥ 60 or AST≥3 months.

show abstract

“…Aidi Injection (ADI, Z52020236, China Food and Drug Administration), which contains extracts of Astragali Radix, Acanthopanax senticosus, Ginseng Radix and Mylabris is widely used in China for the treatment of HCC. Several clinical studies have shown that combining ADI with chemotherapy reduces the toxicity of chemotherapy, enhances clinical e cacy and improves the quality of life of cancer patients [4,5,6,7]. Cantharidin, the major bioactive component of Cantharis, has potent antitumor activity, induces apoptosis in a variety of tumor cells, increases numbers of white blood cells and reduces the occurrence of bone marrow suppression [8,9,11].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic herb-drug interactions between Aidi injection and Doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma

Pan

Zhu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Aidi Injection (ADI), a Chinese herbal preparation with anti-cancer activity, is used for the treatment of hepatocellular carcinoma (HCC). Several clinical studies have shown that co-administration of ADI with doxorubicin (DOX) is associated with reduced toxicity of chemotherapy, enhanced clinical efficacy and improved quality of life for patients. However, limited information is available about the herb-drug interactions between ADI and DOX. The study aimed to investigate the pharmacokinetic mechanism of herb-drug interactions between ADI and DOX in a rat model of HCC. Methods: Experimental HCC was induced in rats by oral administration of diethylnitrosamine. The HCC rats were pretreated with ADI (10 mL/kg, intraperitoneal injection) for 14 consecutive days prior to administration of DOX (7 mg/kg, intravenous injection) to investigate pharmacokinetic interactions. Plasma concentrations of DOX and its major metabolite, doxorubicinol (DOXol), were determined using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Results: Preadministration of ADI significantly altered the pharmacokinetics of DOX in HCC rats, leading to increased plasma concentrations of both DOX and DOXol. The area under the plasma drug concentration-time curve (AUCs) of DOX and DOXol in rats pretreated with ADI were 3.79-fold and 2.92-fold higher, respectively, than those in control rats that did not receive ADI. Conclusions: Increased levels of DOX and DOXol were found in the plasma of HCC rats pretreated with ADI.

show abstract

Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

Cited by 18 publications

References 43 publications

Blended Learning Compared to Traditional Learning in Medical Education: Systematic Review and Meta-Analysis

Blended Learning Compared to Traditional Learning in Medical Education: Systematic Review and Meta-Analysis

The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

Pharmacokinetic herb-drug interactions between Aidi injection and Doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma

Contact Info

Product

Resources

About